Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation

British Journal of Haematology

Volumn 142, Issue 5, 2008, Pages 786-792

  Alousi, Amin M ^a   Saliba, Rima M ^a   Okoroji, Grace Julia ^a   Macapinlac, Homer A ^a   Hosing, Chitra ^a   Korbling, Martin ^a   Samuels, Barry I ^a   Popat, Uday ^a   Kebriaei, Partow ^a   Anderlini, Paolo ^a   Qazilbash, Muzaffar H ^a   De Lima, Marcos ^a   Giralt, Sergio A ^a   Champlin, Richard E ^a   Khouri, Issa F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B cell lymphoma; Lymphomas; Positron emission tomography imaging; Rituximab; Stem cell transplantation

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER SCINTISCANNING; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES; WHOLE BODY IMAGING;

EID: 48949092200     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07277.x     Document Type: Article

References (22)

1. Belhadj, K., fau-Larue, M.H., Elgnaoui, T., Beaujean, F., Beaumont, J.L., Pautas, C., Gaillard, I., Kirova, Y., Allain, A., Gaulard, P., Farcet, J.P., Reyes, F. Haioun, C. (2004) Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Annals of Oncology, 15, 504 510.
2. Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F. Philip, T. (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood, 92, 3562 3568.
3. Brugger, W., Hirsch, J., Grunebach, F., Repp, R., Brossart, P., Vogel, W., Kopp, H.G., Manz, M.G., Bitzer, M., Schlimok, G., Kaufmann, M., Ganser, A., Fehnle, K., Gramatzki, M. Kanz, L. (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Annals of Oncology, 15, 1691 1698.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579 586.
5. Cremerius, U., Fabry, U., Wildberger, J.E., Zimny, M., Reinartz, P., Nowak, B., Schaefer, W., Buell, U. Osieka, R. (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 30, 103 111.
6. Filmont, J.E., Czernin, J., Yap, C., Silverman, D.H., Quon, A., Phelps, M.E. Emmanouilides, C. (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest, 124, 608 613.
7. Galimberti, S., Guerrini, F., Morabito, F., Palumbo, G.A., Di, R.F., Papineschi, F., Caracciolo, F., Fazzi, R., Cervetti, G., Cuzzocrea, A. Petrini, M. (2003) Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplantation, 32, 57 63.
8. Gulati, S., Yahalom, J., Acaba, L., Reich, L., Motzer, R., Crown, J., Toia, M., Igarashi, T., Lemoli, R. Hanninen, E. (1992) Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. Journal of Clinical Oncology, 10, 936 941.
9. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F. Meignan, M. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 106, 1376 1381.
10. International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987 994.
11. Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. Cheson, B.D. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 25, 571 578.
12. Kaplan, E.L. Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457 481.
13. Khouri, I.F., Saliba, R.M., Hosing, C., Okoroji, G.J., Acholonu, S., Anderlini, P., Couriel, D., de, L.M., Donato, M.L., Fayad, L., Giralt, S., Jones, R., Korbling, M., Maadani, F., Manning, J.T., Pro, B., Shpall, E., Younes, A., McLaughlin, P. Champlin, R.E. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 23, 2240 2247.
14. Magni, M., Di, N.M., Devizzi, L., Matteucci, P., Lombardi, F., Gandola, L., Ravagnani, F., Giardini, R., Dastoli, G., Tarella, C., Pileri, A., Bonadonna, G. Gianni, A.M. (2000) Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 96, 864 869.
15. Philip, T., Armitage, J.O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J.Y., Colombat, P., Goldstone, A.H., Gorin, N.C. Flesh, M. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 316, 1493 1498.
16. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y. Harousseau, J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540 1545.
17. Prentice, R.L., Kalbfleisch, J.D., Peterson, A.V., Jr., Flournoy, N., Farewell, V.T. Breslow, N.E. (1978) The analysis of failure times in the presence of competing risks. Biometrics, 34, 541 554.
18. Schot, B., van Imhoff, G., Pruim, J., Sluiter, W., Vaalburg, W. Vellenga, E. (2003) Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. British Journal of Haematology, 123, 282 287.
19. Schot, B.W., Pruim, J., van Imhoff, G.W., Sluiter, W.J., Vaalburg, W. Vellenga, E. (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica, 91, 490 495.
20. Shimoni, A., Hardan, I., Avigdor, A., Yeshurun, M., Raanani, P., Ben-Bassat, I. Nagler, A. (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. British Journal of Haematology, 122, 457 464.
21. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 53 59.
22. Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., Gordon, B. Armitage, J.O. (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 1846 1851.